MicroRNA profiling of Parkinson's disease brains identifies early downregulation of miR-34b/c which modulate mitochondrial function.
暂无分享,去创建一个
Xavier Estivill | Isidre Ferrer | X. Estivill | G. Escaramís | I. Ferrer | Y. Espinosa-Parrilla | E. Martí | Elena Miñones-Moyano | S. Porta | B. Kagerbauer | R. Rabionet | S. Iraola | Raquel Rabionet | Sílvia Porta | Eulàlia Martí | Georgia Escaramís | Elena Miñones-Moyano | Susana Iraola | Birgit Kagerbauer | Yolanda Espinosa-Parrilla | Susana Iraola
[1] M. Toyota,et al. Methylation-associated silencing of microRNA-34b/c in gastric cancer and its involvement in an epigenetic field defect. , 2010, Carcinogenesis.
[2] Changan Jiang,et al. Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin , 2006, Nature.
[3] Jingwen Liu,et al. Abnormal activation of the synuclein-gamma gene in hepatocellular carcinomas by epigenetic alteration. , 2006, International journal of oncology.
[4] K. Fountas,et al. Genetic basis of Parkinson disease. , 2010, Neurosurgical focus.
[5] J. Simpkins,et al. Neuroprotective effects of 17beta-estradiol and nonfeminizing estrogens against H2O2 toxicity in human neuroblastoma SK-N-SH cells. , 2006, Molecular pharmacology.
[6] A. Lang,et al. Involvement of the cerebellothalamocortical pathway in Parkinson disease , 2010, Annals of neurology.
[7] Joachim Klose,et al. Mitochondrial Dysfunction and Oxidative Damage in parkin-deficient Mice* , 2004, Journal of Biological Chemistry.
[8] Jörn Lewin,et al. Quantitative DNA methylation analysis based on four-dye trace data from direct sequencing of PCR amplificates , 2004, Bioinform..
[9] C. Marsden,et al. Mitochondrial Complex I Deficiency in Parkinson's Disease , 1990, Lancet.
[10] G. Schratt. microRNAs at the synapse , 2009, Nature Reviews Neuroscience.
[11] Guilherme J M Rosa,et al. A powerful and flexible linear mixed model framework for the analysis of relative quantification RT-PCR data. , 2009, Genomics.
[12] D. Mann,et al. Parkinson disease: Progress towards a molecular biomarker for Parkinson disease , 2010, Nature Reviews Neurology.
[13] W. Schulz-Schaeffer. The synaptic pathology of α-synuclein aggregation in dementia with Lewy bodies, Parkinson’s disease and Parkinson’s disease dementia , 2010, Acta Neuropathologica.
[14] S. Murayama,et al. Lewy body-related alpha-synucleinopathy in aging. , 2004, Journal of neuropathology and experimental neurology.
[15] Philip L De Jager,et al. Parkinson's disease: genetics and pathogenesis. , 2011, Annual review of pathology.
[16] P. Zamore,et al. Small silencing RNAs: an expanding universe , 2009, Nature Reviews Genetics.
[17] M. Toyota,et al. Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. , 2008, Cancer research.
[18] K. Jellinger. Lewy body-related alpha-synucleinopathy in the aged human brain. , 2004, Journal of neural transmission.
[19] Sabine Borwege,et al. Terminally differentiated SH-SY5Y cells provide a model system for studying neuroprotective effects of dopamine agonists , 2009, Neurotoxicity Research.
[20] Thomas D. Schmittgen,et al. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.
[21] Y. Mizuno,et al. p53 protein, interferon-γ, and NF-κB levels are elevated in the parkinsonian brain , 2007, Neuroscience Letters.
[22] O. Rascol,et al. Motor activation in multiple system atrophy and Parkinson disease , 2010, Neurology.
[23] T. Peng,et al. Mitochondrial dysfunction in Parkinson's disease. , 1999, Biochemical Society symposium.
[24] A. Hofman,et al. Prevalence of Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. , 2000, Neurology.
[25] J. C. Greene,et al. Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[26] D. Chan,et al. Mitochondrial dynamics–fusion, fission, movement, and mitophagy–in neurodegenerative diseases , 2009, Human molecular genetics.
[27] A. Schapira. Mitochondria in the aetiology and pathogenesis of Parkinson's disease. , 1999, The Lancet. Neurology.
[28] I. Ferrer,et al. Human brain cortex: mitochondrial oxidative damage and adaptive response in Parkinson disease and in dementia with Lewy bodies. , 2009, Free radical biology & medicine.
[29] Hansjürgen Bratzke,et al. Stages in the development of Parkinson’s disease-related pathology , 2004, Cell and Tissue Research.
[30] Lewy Body‐Related α‐Synucleinopathy in Aging , 2004 .
[31] C. Marsden,et al. Anatomic and Disease Specificity of NADH CoQ1 Reductase (Complex I) Deficiency in Parkinson's Disease , 1990, Journal of neurochemistry.
[32] Izumi Horikawa,et al. Nutlin-3a activates p53 to both down-regulate inhibitor of growth 2 and up-regulate mir-34a, mir-34b, and mir-34c expression, and induce senescence. , 2008, Cancer research.
[33] Teresa García,et al. [Phosphorylation of tau and Alzheimer's disease]. , 2004, Gaceta medica de Mexico.
[34] J. Im,et al. Repression of α-synuclein expression and toxicity by microRNA-7 , 2009, Proceedings of the National Academy of Sciences.
[35] R. Swerdlow,et al. Complex I deficiency in Parkinson's disease frontal cortex , 2008, Brain Research.
[36] W. Dauer,et al. Parkinson's Disease Mechanisms and Models , 2003, Neuron.
[37] Hansong Deng,et al. The Parkinson's disease genes pink1 and parkin promote mitochondrial fission and/or inhibit fusion in Drosophila , 2008, Proceedings of the National Academy of Sciences.
[38] D. Nicholl,et al. Genetics of Parkinson’s disease and parkinsonism , 2007, Expert review of neurotherapeutics.
[39] A. Kakita,et al. Proteinase K-resistant α-synuclein is deposited in presynapses in human Lewy body disease and A53T α-synuclein transgenic mice , 2010, Acta Neuropathologica.
[40] Isidre Ferrer,et al. Early involvement of the cerebral cortex in Parkinson's disease: Convergence of multiple metabolic defects , 2009, Progress in Neurobiology.
[41] M. Guo,et al. Pink1, Parkin, DJ-1 and mitochondrial dysfunction in Parkinson's disease , 2007, Current Opinion in Neurobiology.
[42] Gaofeng Wang,et al. Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of alpha-synuclein. , 2008, American journal of human genetics.
[43] L. Skipper,et al. Pathogenic mutations in Parkinson disease , 2007, Human mutation.
[44] Wei Wang,et al. MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. , 2007, Cancer research.
[45] F. Gao. Posttranscriptional control of neuronal development by microRNA networks , 2008, Trends in Neurosciences.
[46] Olivier Voinnet,et al. Revisiting the principles of microRNA target recognition and mode of action , 2009, Nature Reviews Molecular Cell Biology.
[47] A. Lees,et al. Differential DJ-1 gene expression in Parkinson's disease , 2009, Neurobiology of Disease.
[48] Wei Zhao,et al. Loss of epigenetic control of synuclein-gamma gene as a molecular indicator of metastasis in a wide range of human cancers. , 2005, Cancer research.
[49] S. Ropero,et al. A microRNA DNA methylation signature for human cancer metastasis , 2008, Proceedings of the National Academy of Sciences.
[50] M. Cameron Sullards,et al. Oxidative Damage of DJ-1 Is Linked to Sporadic Parkinson and Alzheimer Diseases* , 2006, Journal of Biological Chemistry.
[51] K. Jellinger. Lewy body-related α-synucleinopathy in the aged human brain , 2004, Journal of Neural Transmission.
[52] G. Hannon,et al. A MicroRNA Feedback Circuit in Midbrain Dopamine Neurons , 2007, Science.
[53] J. Simpkins,et al. Neuroprotective Effects of 17β-Estradiol and Nonfeminizing Estrogens against H2O2 Toxicity in Human Neuroblastoma SK-N-SH Cells , 2006, Molecular Pharmacology.
[54] K. Sonntag,et al. MicroRNAs and deregulated gene expression networks in neurodegeneration , 2010, Brain Research.
[55] C. Marsden,et al. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease , 1994, Annals of neurology.
[56] H. Braak,et al. Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.
[57] G. Muntané,et al. Phosphorylation of tau and α-synuclein in synaptic-enriched fractions of the frontal cortex in Alzheimer’s disease, and in Parkinson’s disease and related α-synucleinopathies , 2008, Neuroscience.
[58] David S. Park,et al. Loss of the Parkinson's disease-linked gene DJ-1 perturbs mitochondrial dynamics. , 2010, Human molecular genetics.
[59] Angela C. Poole,et al. The PINK1/Parkin pathway regulates mitochondrial morphology , 2008, Proceedings of the National Academy of Sciences.
[60] T. Niki,et al. DJ‐1 has a role in antioxidative stress to prevent cell death , 2004, EMBO reports.
[61] F. Checler,et al. Apoptosis in Parkinson's disease: is p53 the missing link between genetic and sporadic Parkinsonism? , 2011, Cellular signalling.
[62] Ted M. Dawson,et al. Understanding microRNAs in neurodegeneration , 2009, Nature Reviews Neuroscience.
[63] G. Mardon,et al. Drosophila parkin mutants have decreased mass and cell size and increased sensitivity to oxygen radical stress , 2004, Development.
[64] Thomas Floss,et al. Sensitivity to Oxidative Stress in DJ-1-Deficient Dopamine Neurons: An ES- Derived Cell Model of Primary Parkinsonism , 2004, PLoS biology.
[65] T. Dawson,et al. The role of parkin in familial and sporadic Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.